NexDx develops molecular diagnostic products and services aimed at personalized medicine for rheumatoid arthritis and other autoimmune diseases. The company’s core product is a lead molecular diagnostic test for rheumatoid arthritis. It intends to use recent funding to support ongoing research and development and to advance that lead test into analytical and clinical validation. NexDx was founded in August 2011 by Chairman and CEO Jonathan E. Lim, M.D., and Gary S. Firestein, M.D., a professor of medicine at UC San Diego. The company is based in San Diego, CA. Recent financings were secured to fund its R&D and validation efforts.

Total raised

$3M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2012